SARS-CoV-2-IN-14
SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].
Product Specifications
CAS Number
22203-98-1
UNSPSC
12352005
Hazard Statement
H302
Target
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/sars-cov-2-in-14.html
Purity
99.02
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C1=C(C=CC(Cl)=C1)O)NC2=CC(Cl)=CC=C2
Molecular Formula
C13H9Cl2NO2
Molecular Weight
282.12
Precautions
P264-P270-P330-P501
References & Citations
[1]Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD44 Standard (156-3C11), CF594 conjugate, 0.1mg/mL
Ep-CAM / CD326 (VU-1D9), CF640R conjugate, 0.1mg/mL
Human IgG Immunoglobulin (IG266), CF405S conjugate, 0.1mg/mL
TAG-72 / CA72.4 (B72.3), CF405S conjugate, 0.1mg/mL
